Eye Care (Ophthalmology)
Optimax's healthy cash flow and financial position have facilitated sustained long term growth of the Company
Optimax Holdings Berhad (“Optimax” or the “Company”), one of the industry’s established private eye specialist service providers, today announced the Company proposed to transfer its listing to the Main Market of Bursa Securities from ACE Market and proposed adoption of a new Constitution of Optimax to facilitate the implementation of the transfer.
Optimax has met the requirements for the transfer of its listing as set out in the Equity Guidelines issued by the Securities Commission Malaysia (“SC”) and the Main Market Listing Requirements (“MMLR”) of Bursa Securities. Optimax has met the profit requirement with an aggregate after-tax profit of at least RM20.00 million for the past 3 to 5 full financial years and an after-tax profit for the most recent financial year of at least RM6.00 million.
Meanwhile, Optimax has a solid financial position and liquidity with no accumulated losses, current assets and current liabilities of RM33.52 million and RM13.97 million respectively, representing a current ratio of 2.40 times as well as cash and bank balances of RM19.61 million as at 31 December 2021. Optimax has also generated positive net cash flow from operating activities of RM19.69 million in FY21 and has consistently done so since 2017.
Ms. Sandy Tan (“Sandy”), Chief Executive Officer of Optimax, said: “We believe that the transfer from the Main Market of Bursa Securities from ACE Market will enhance the Company’s credibility, prestige, and reputation as well as accord the Company with greater recognition and support amongst investors and all stakeholders while reflecting Optimax’s current scale of operations. This in turn is expected to improve the liquidity and marketability of Optimax Shares.”
“We have also proposed the adoption of a new Constitution of Optimax as we believe that it is necessary to facilitate the implementation of the main market transfer and ensuring the Company’s compliance with the MMLR.”
“We are confident that the main market transfer will be approved by the relevant authorities, as we continue to expand our business operations by extending our ambulance care centres (“ACC”) network to connect the major states and set up more satellite clinics within Malaysia to reach patients in remote areas.”
“The main market transfer will mark another major milestone in the achievement of Optimax after our listing on the ACE Market of Bursa Securities on 18 August 2020. Barring any unforeseen circumstances and subject to all required approvals being obtained, we are hopeful that the main market transfer can be completed by the Q4 of 2022.”
Based on the Record of Depositors of Optimax as at 6 May 2022 (“LPD”), approximately 33.70% of the total number of issued Shares were held by 3,570 public shareholders holding not less than 100 Shares each.
Age-related Macular Degeneration in a Nutshell
What we need to know about Age-related Macular Degeneration: What is Age-related Macular Degeneration (AMD)? It is an age-related eye disease that causes central vision loss, more commonly in people above the age of 50 years old.Read more
The Gift Of Sight: How To Identify Lazy Eye (Amblyopia) and Why It Should Be Treated from the Start
Early screenings and awareness of the condition are key to reversing such eye conditions and preventing more severe complications in adulthoodRead more
Optimax Sets New Record in Malaysia: Most Refractive Eye Treatments Awarded by Malaysia Book of Records
Optimax, a top vision correction provider in Malaysia, receives the prestigious Malaysia Book of Records Award for the highest number of refractive eye treatments. Discover their remarkable accomplishment in delivering exceptional eye care solutions.Read more
AsiaMedic Sets New Standard in Healthcare with Installation of First SIGNA™ Hero 3.0T MRI Scanner in Asia-Pacific
AsiaMedic, a leading health screening and diagnostic imaging specialist, has taken a groundbreaking leap in healthcare innovation with the installation of the first-ever SIGNA™ Hero 3.0T magnetic resonance imaging (MRI) scanner in the Asia-Pacific region, on its premises. This revolutionary milestone reinforces AsiaMedic's commitment to advancing patient care through cutting-edge technology. The SIGNA™ Hero 3.0T MRI scanner acquired from GE HealthCare is poised to offer enhanced imaging quality, faster scan times, and redefine diagnostic precision.Read more
Decoding Dark Eye Circles: Explore Effective Solutions for a Lasting Brightness
Dark eye circles, the elusive shadows beneath our eyes, are a cause of concern for many and can be more than just a sign of fatigue. Also known as preorbital discolouration, dark eye circles can make you look tired, aged, and unlike yourself. However, in order to combat this common concern, understanding what they are and the science behind them is the key to creating the most effective solution. Let’s delve into the world of dark-eye circles, unveil the mysteries behind these pesky shadows and learn how you can banish them for good.Read more
Unlocking Your Health Potential Through Functional Medicine
Functional medicine is a personalized approach to healthcare that focuses on identifying and addressing the root causes of disease. It emphasizes understanding the individual's unique genetic, lifestyle, and environmental factors that contribute to their health. Functional medicine practitioners use a variety of tools, including in-depth assessments, laboratory tests, and personalized treatment plans, to help individuals achieve optimal well-being.Read more